Efficacy and Safety Outcomes of Intravitreal Dexamethasone Implant Therapy for the Treatment of Adult Coats’ Disease

Table 2

Baseline clinical characteristics of patients with Stage 3A Coats’ disease.

Case no.	Age/gender	Systemic disease	Prior treatment	BCVA (logMAR)	CRT (μm)	IOP (mmHg)	Retinal details at first visit
Case 1	41/male	Fatty liver disease	Intravitreal ganciclovir	1.0	552	12.8	Exudative retinal detachment
Case 2	52/male	None	IVC, laser	1.4	228	10	Subtotal ERD with massive exudates
Case 3	59/male	None	None	1.85	1492	13.9	Subtotal ERD with massive exudates and epiretinal membrane
Case 4	40/male	None	Laser	1.85	2111	13	Subtotal ERD with subretinal hemorrhage
Case 5	45/male	None	IVR	1.3	732	14.2	Extensive peripheral retinal vascular telangiectasia
Case 6	47/female	None	None	0.3	707	15	Subtotal ERD with massive exudates
Case 7	36/male	None	None	0.5	640	16	Considerable exudation involving the posterior pole
Case 8	46/female	None	None	0.2	291	13	Subtotal ERD with massive exudates
Case 9	34/male	None	IVC, laser	1.85	290	13	Subtotal ERD with massive exudates
Case 10	42/male	Diabetic	None	0.5	310	15.9	Subtotal ERD with massive exudates

BCVA: best-corrected visual acuity. logMAR: 10 logarithm of minimum angle of resolution letters. CRT: central retinal thickness. IOP: intraocular pressure. DEX: dexamethasone intravitreal implant. IVC: intravitreal injection of conbercept. PPV: pars plana vitrectomy. ERD: exudative retinal detachment.